Target intelligence / Profile preview

Ubiquitin-like containing PHD and RING finger domain 1 (UHRF1)

Target
UHRF1
Molecular classification
E3 ubiquitin ligase, Epigenetic regulator, Chromatin-associated protein, Histone modification, DNA methylation-associated protein
01

Overview

Ubiquitin-like containing PHD and RING finger domain 1 (UHRF1) is an epigenetic regulator and E3 ubiquitin ligase involved in the maintenance of DNA methylation, histone modification, and chromatin structure. It recognizes hemi-methylated DNA and recruits DNA methyltransferases (notably DNMT1) during DNA replication to preserve epigenetic marks[1][2][3]. UHRF1 functions as a master coordinator of multiple chromatin-modifying proteins and plays a crucial role in cell cycle control and tumor suppressor gene silencing through epigenetic mechanisms[2]. Aberrant overexpression of UHRF1 is observed in multiple types of cancer and is associated with poor prognosis, making it both a promising therapeutic target and a biomarker for diagnosis and prognosis in oncology[1][2][3]. UHRF1 exerts non-enzymatic reader functions via multiple domains (UBL, TTD, PHD, SRA, RING) to interact with histone modifications and DNA, orchestrating silencing of tumor suppressor genes and maintenance of epigenetic states[2][3].

Other names
ICBP90NP95RNF106Inverted CCAAT box-binding protein of 90 kDaNuclear protein 95
02

Mechanism of action

Inhibition of E3 ubiquitin ligase activity; Disruption of DNA methylation maintenance; Inhibition of protein-protein interactions with DNMT1

03

Biological functions

Maintenance of DNA methylationEpigenetic gene silencingCell cycle regulation (particularly G1/S transition)Recruitment and regulation of DNA methyltransferases (DNMT1, DNMT3A, DNMT3B)Chromatin remodelingRegulation of p53-dependent DNA damage checkpoint
04

Disease associations

Cancer (oncogene in various cancers: hepatocellular carcinoma, prostate cancer, etc.)Potential roles in other epigenetic diseases (largely studied in the context of cancer)
05

Safety considerations

Potential for global genomic hypomethylation if targeted, which could trigger inappropriate gene activation or genome instability[2].Possible off-target effects due to broad involvement in essential epigenetic regulation
06

Interacting drugs

No specific approved drugs directly targeting UHRF1 are listed in these sources; however, it is under investigation as a drug target in cancer. UHRF1-modulating compounds are in early drug discovery and preclinical study.
07

Biomarkers

UHRF1 expression is a diagnostic and prognostic biomarker for a wide range of cancers, including hepatocellular carcinoma and prostate cancer[2].

Beyond the preview

Go deeper on Ubiquitin-like containing PHD and RING finger domain 1 (UHRF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ubiquitin-like containing PHD and RING finger domain 1 (UHRF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call